MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition is a research paper published in The Journal of Experimental Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 50 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: P30 CA042014
National Cancer Institute
Grant: F30 CA235964
National Cancer Institute
Grant: R01 CA131261
National Cancer Institute
Grant: R01 CA176839
National Cancer Institute
Grant: K08 CA230151
Lustgarten Foundation
Grant: SU2C-AACR-PCC-04-18
National Institutes of Health
Grant: 5R01CA176839-02
Targeting Oncogenic BRAF And PI3'-Kinase Signaling For Melanoma Therapy
National Institutes of Health
Grant: 3P30CA042014-30S2
Cancer Center Support Grant
National Institutes of Health
Grant: 3R01CA131261-11S1
Studying the initiation, progression and therapy of lung cancer in mouse models
National Institutes of Health
Grant: 5K08CA230151-03
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
National Institutes of Health
Grant: 5F30CA235964-03
Defining the role of aberrant signal pathway activation in melanoma on the immune microenvironment
Huntsman GI Disease Center
University of Utah
HCI Preclinical Research Shared Resource
Five for the Fight
Pfizer Consumer Healthcare
Huntsman Cancer Foundation
V Foundation
FWCI
6.28
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals